TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Genetic and epigenetic changes of the tumor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Bone mineral density measured by DXA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with Grade 3 or 4 possibly related adverse event (PRAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Antibacterial activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti-inflammatory activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent progression free survival
Endpoint domain: Mortality/survival
Primary endpoint: Successful receipt of text messages
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Adjustment Disorder
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Peripheral circulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Circulating lipid and carbohydrate metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Basal and post-exercise gene expression with inactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in postoperative cognitive function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in periaqueductal gray region (PAG) activation - looming task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in PAG activation - resting
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Arterial stiffness Change from Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Blood pressure Change from Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Gut microbiome composition Change from Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of immune related adverse events (irAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Leucocytes telomere length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of pCLE-targeted optical biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax: Maximum Observed Plasma Concentration for Brigatinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUClast: Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration for Brigatinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCinf: Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity for Brigatinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence rate and grade of dose-limiting toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: SI-053 related adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative rate of toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: functional WHODAS 2.0 score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Sex Hormone Binding Globulin (SHBG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Frequency of solicited local reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of blood smear positive individuals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Kidney Disease Knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: CKD Self-Management
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: AMR resolution rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Motor praxia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Radiographic evidence of calculus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiographic measure of alveolar bone loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical evidence of calculus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical measure of alveolar bone loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of ADEs
Endpoint domain: Adverse events/effects
Primary endpoint: Induced VF Conversion Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Correlation with MRI PDFF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perioperative change in hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage change in the time to complete the nine-hole peg test (9-HPT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage change in amplitude of motor evoked potential (MEP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from baseline Blood Oxygen Level-Dependent (BOLD) activation in the cortical grasp network
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Vocal audiometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Visual Analog Scale-Anxiety (VAS-A) Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in State Trait Anxiety Inventory (STAI) Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Semispinalis capitis state of tension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Sternocleidomastoideus (SCM) state of tension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Trapezius state of tension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Deltoid state of tension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Biceps brahii state of tension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Score on Social Competence Scale - Parent (SCP)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Score on Difficulties in Emotion Regulation Scale (DERS) - Teacher
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Bladder-intact event-free survival (BI-EFS)
Endpoint domain: Mortality/survival
Primary endpoint: Patient global impression of Improvement (PGI-I)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Right ventricular contractility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Right ventricular lusitropy (diastolic function)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of Rituximab Emergent Cardiovascular Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Heart Failure Hospitalisation Incidence
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Occurrence of cardiac arrhythmias and conduction disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Delay to treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Cmax of docetaxel injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC of docetaxel injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prediction of unfavorable outcome
Endpoint domain: Mortality/survival
Primary endpoint: Change in Blood Creatine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cough test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: craving severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: heroin craving
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with improved primary outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants discontinuing study intervention due to AE
Endpoint domain: Adverse events/effects
Primary endpoint: HPV Clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wall Strain Index for Potential Detection of Intramyocardial Hemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Wall Strain Index in Detecting the Severity of Intramyocardial Hemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Wall Strain Index Ratio in Identification of Vulnerable LV Segments for Cardiac Rupture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of treatment-related adverse events (AEs) and serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Asthma Quality of Life Scale for Children
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Adolescent Asthma Self-Efficacy Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Nephrotic syndrome remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of clinically meaningful chemotherapy induced peripheral neuropathy (CIPN)
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of positive repeat biopsy for malignancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Maximal intraprocedural pain level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Achievement of Viral Suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Experiencing Major Adverse Kidney Events (MAKE)
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy endpoint
Endpoint domain: Physiological/clinical
Primary endpoint: Incidence and proportion of participants with selected Adverse Events (AEs) and Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Standardized uptake value of 18F-FES
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lesions detected by 18F-FES PET/CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Opioid refills/requests
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Total number of adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Total number of serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in maximal voluntary isometric muscle contraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in countermovement jump height
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in delayed onset of muscle soreness (DOMS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Proportion of notifications addressed within 7 days
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Pressure profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation between patient estimates and actual risk estimates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of 30-days re-admission
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: test scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Acceptability of Higher Metformin Dose
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Feasibility of Higher Metformin Dose
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Muscle and tendon stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Baseline in vital signs value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Baseline in 12-ECG values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Degrees of Gait Profile Score overall
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Score change in liking/wanting of each e-cigarette condition
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Score change in drug effects of each e-cigarette condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Score change in irritation of harshness of each e-cigarette condition
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Prostate volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fear Scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: fat free mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of RAPA-201 Cell Therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Operative time in minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of patients with any adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Quality of Life (emPHasis-10)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Prevalence of rheumatic heart disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in malaria prevalence in children under 5 years at 1st year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Changes in malaria prevalence in children under 5 years at 2nd year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Levels of HIF-1 Alpha, VEGF and MMP-8
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Dyads That Opt Out of the Intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Pharmacist Messages to the PCP That Receive an Acknowledgment or Response
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of Dyads Who Complete 2 of 2 Pharmacist Phone Calls Based on Documented Status Reports
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change from Baseline Coma Recovery Scale - Revised (CRS-R)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Adherence to Intervention
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Sensitivity and specificity of [18F]PSMA-1007 PET/CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Generalized Anxiety Disorder -7 (GAD-7)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Quality of Postpartum Cesarean Recovery Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Self Reported Anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Progressively deterioration in acute phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Bad prognosis of acute ischemia stroke
Endpoint domain: Mortality/survival
Primary endpoint: Change in Fitbit-recorded average steps per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Fitbit-recorded average active minutes per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Circulating C-peptide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of Participants with Abnormalities in Vital Signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with Abnormalities in Electrocardiogram (ECG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants with Abnormalities in Clinical Safety Laboratory Parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with Abnormalities in Physical Examinations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of PAHs present in sweat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of aerobic endurance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of concentration of testosterone in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change of blood PDE5 gene expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of underdosage at the seminal vesicles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Copenhagen Neck Functional Disability Scale (CNFDS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: 1-year Progression free survival (PFS)
Endpoint domain: Mortality/survival
Primary endpoint: Improved ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Better voice quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants with sustained remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in percentage of glycemic control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in percentage of blood pressure control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Frequency of AEs, SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Blood pressure monitor accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of pre-defined safety criteria or dose-limiting toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Difference in maternal vitamin D status (25OHD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Difference in maternal 3-epi-25-Hydroxyvitamin D
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Difference in maternal 1,25-dihydroxyvitamin D
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Difference in maternal vitamin D binding proteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Sensitivity and specificity of cHS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HPV vaccine coverage (≥ 1 dose)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Plasma-total carbon dioxide (CO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Weight Loss through 16 sessions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percent Weight Loss through the 12 month trial
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Volume change in the palatal donor region
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of successful initial spontaneous breathing trials
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Daily wear time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: OCT retinal and choroidal thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Retinal Photography vascular caliber
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: functional connection strength in the brain network
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean change in COPD Assessment Test (CAT) score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Drug adherence score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Complete response during the overall phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to the reduced-sodium salt intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Safety and tolerability of SL-172154 with PLD
Endpoint domain: Adverse events/effects
Primary endpoint: Safety and tolerability of SL-172154 with MIRV
Endpoint domain: Adverse events/effects
Primary endpoint: Recommended Phase 2 dose (RP2D) for SL-172154 with PLD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Recommended Phase 2 dose (RP2D) for SL-172154 with MIRV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of touchpoints with narrative medicine expert/guide
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of participants who complete the writing exercise
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention